Advertisement

Nutrafoods

, Volume 14, Issue 3, pp 111–117 | Cite as

A nutraceutical role for cannabidiol. Why not?

A review of its pharmacological properties and clinical applications
  • Francesco Di Pierro
Editorial
  • 83 Downloads

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Bergamaschi MM, Queiroz RH, Zuardi AW, Crippa JA (2011) Safety and side effects of cannabidiol, a Cannabis sativa constituent. Curr Drug Saf 6(4):237–449CrossRefGoogle Scholar
  2. 2.
    Gopalakrishnan R, Sundaram J, Sattu K, Pandi A, Thiruvengadam D (2013) Dietary supplementation of silymarin is associated with decreased cell proliferation, increased apoptosis, and activation of detoxification system in hepatocellular carcinoma. Mol Cell Biochem 377(1–2):163–176CrossRefGoogle Scholar
  3. 3.
    Pagano E, Laudato M, Griffo M, Capasso R (2014) Phytotherapy of benign prostatic hyperplasia. A minireview. Phytother Res 28(7):949–955CrossRefGoogle Scholar
  4. 4.
    Byelashov OA, Sinclair AJ, Kaur G (2015) Dietary sources, current intakes, and nutritional role of omega-3 docosapentaenoic acid. Lipid Technol 27(4):79–82CrossRefGoogle Scholar
  5. 5.
    Himmerich H, Erbguth F (2014) Nutrition and dietary supplements in psychiatric diseases. Nervenarzt 85(12):1512–1520CrossRefGoogle Scholar
  6. 6.
    Eichler M, Spinedi L, Unfer-Grauwiler S, Bodmer M, Surber C, Luedi M, Drewe J (2012) Heat exposure of Cannabis sativa extracts affects the pharmacokinetic and metabolic profile in healthy male subjects. Planta Med 78(7):686–691CrossRefGoogle Scholar
  7. 7.
    De Backer B, Debrus B, Lebrun P, Theunis L, Dubois N, Decock L, Verstraete A, Hubert P, Charlier C (2009) Innovative development and validation of an HPLC/DAD method for the qualitative and quantitative determination of major cannabinoids in cannabis plant material. J Chromatogr B Analyt Technol Biomed Life Sci 877(32):4115–4124CrossRefGoogle Scholar
  8. 8.
    Desrosiers NA, Himes SK, Scheidweiler KB, Concheiro- Guisan M, Gorelick DA, Huestis MA (2014) Phase I and II cannabinoid disposition in blood and plasma of occasional and frequent smokers following controlled smoked cannabis. Clin Chem 60(4):631–643CrossRefGoogle Scholar
  9. 9.
    Huestis MA (2005) Pharmacokinetics and metabolism of the plant cannabinoids, delta9-tetrahydrocannabinol, cannabidiol and cannabinol. Handb Exp Pharmacol (168):657–690CrossRefGoogle Scholar
  10. 10.
    Lee D, Schwope DM, Milman G, Barnes AJ, Gorelick DA, Huestis MA (2012) Cannabinoid disposition in oral fluid after controlled smoked cannabis. Clin Chem 58(4):748–756CrossRefGoogle Scholar
  11. 11.
    Paudel KS, Hammell DC, Agu RU, Valiveti S, Stinchcomb AL (2010) Cannabidiol bioavailability after nasal and transdermal application: effect of permeation enhancers. Drug Dev Ind Pharm 36(9):1088–1097CrossRefGoogle Scholar
  12. 12.
    Petitet F, Jeantaud B, Reibaud M, Imperato A, Dubroeucq MC (1998) Complex pharmacology of natural cannabinoids: evidence for partial agonist activity of delta9-tetrahydrocannabinol and antagonist activity of cannabidiol on rat brain cannabinoid receptors. Life Sci 63(1):PL1–PL6Google Scholar
  13. 13.
    Karniol IG, Shirakawa I, Kasinski N, Pfeferman A, Carlini EA (1974) Cannabidiol interferes with the effects of delta 9 - tetrahydrocannabinol in man. Eur J Pharmacol 28(1):172–177CrossRefGoogle Scholar
  14. 14.
    Dalton WS, Martz R, Lemberger L, Rodda BE, Forney RB (1976) Influence of cannabidiol on delta-9-tetrahydrocannabinol effects. Clin Pharmacol Ther 19(3):300–309Google Scholar
  15. 15.
    Neelakantan H, Tallarida RJ, Reichenbach ZW, Tuma RF, Ward SJ, Walker EA (2015) Distinct interactions of cannabidiol and morphine in three nociceptive behavioral models in mice. Behav Pharmacol 26(3):304–314CrossRefGoogle Scholar
  16. 16.
    Grotenhermen F. 12th International Conference of the European Industrial Hemp Association 20–21 May 2015, Wesseling near Cologne, GermanyGoogle Scholar
  17. 17.
    Kozela E, Juknat A, Kaushansky N, Rimmerman N, Ben-Nun A, Vogel Z (2013) Cannabinoids decrease the th17 inflammatory autoimmune phenotype. J Neuroimmune Pharmacol 8(5):1265–1276CrossRefGoogle Scholar
  18. 18.
    Mecha M, Feliú A, Iñigo PM, Mestre L, Carrillo-Salinas FJ, Guaza C (2013) Cannabidiol provides long-lasting protection against the deleterious effects of inflammation in a viral model of multiple sclerosis: a role for A2A receptors. Neurobiol Dis 59:141–150CrossRefGoogle Scholar
  19. 19.
    Li KI, Feng JY, Li YY, Yuece B, Lin XH, Yu LY, Li YN, Feng YJ, Storr M (2013) Anti-inflammatory role of cannabidiol and O-1602 in cerulein-induced acute pancreatitis in mice. Pancreas 42(1):123–129CrossRefGoogle Scholar
  20. 20.
    Ribeiro A, Ferraz-de-Paula V, Pinheiro ML, Vitoretti LB, Mariano-Souza DP, Quinteiro-Filho WM, Akamine AT, Almeida VI, Quevedo J, Dal-Pizzol F, Hallak JE, Zuardi AW, Crippa JA, Palermo-Neto J (2012) Cannabidiol, a non-psychotropic plant-derived cannabinoid, decreases inflammation in a murine model of acute lung injury: role for the adenosine A(2A) receptor. Eur J Pharmacol 678(1–3):78–85CrossRefGoogle Scholar
  21. 21.
    Zuardi AW, Shirakawa I, Finkelfarb E, Karniol IG (1982) Action of cannabidiol on the anxiety and other effects produced by delta 9-THC in normal subjects. Psychopharmacology (Berl) 76(3):245–250CrossRefGoogle Scholar
  22. 22.
    Bisogno T, Hanus L, De Petrocellis L, Tchilibon S, Ponde DE, Brandi I, Moriello AS, Davis JB, Mechoulam R, Di Marzo V (2001) Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. Br J Pharmacol 134(4):845–852CrossRefGoogle Scholar
  23. 23.
    Morelli MB, Offidani M, Alesiani F, Discepoli G, Liberati S, Olivieri A, Santoni M, Santoni G, Leoni P, Nabissi M (2014) The effects of cannabidiol and its synergism with bortezomib in multiple myeloma cell lines. A role for transient receptor potential vanilloid type-2. Int J Cancer 134(11): 2534–2546CrossRefGoogle Scholar
  24. 24.
    Nabissi M, Morelli MB, Amantini C, Liberati S, Santoni M, Ricci-Vitiani L, Pallini R, Santoni G (2015) Cannabidiol stimulates Aml-1a-dependent glial differentiation and inhibits glioma stem-like cells proliferation by inducing autophagy in a TRPV2-dependent manner. Int J Cancer. doi:  10.1002/ijc.29573 Google Scholar
  25. 25.
    Mechoulam R, Parker LA, Gallily R (2002) Cannabidiol: an overview of some pharmacological aspects. J Clin Pharmacol 42(11 Suppl):11S–19SGoogle Scholar
  26. 26.
    Xiong W, Cui T, Cheng K, Yang F, Chen SR, Willenbring D, Guan Y, Pan HL, Ren K, Xu Y, Zhang L (2012) Cannabinoids suppress inflammatory and neuropathic pain by targeting a3 glycine receptors. J Exp Med 209(6):1121–1134CrossRefGoogle Scholar
  27. 27.
    Malfait AM, Gallily R, Sumariwalla PF, Malik AS, Andreakos E, Mechoulam R, Feldmann M (2000) The non-psychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis. Proc Natl Acad Sci U S A 97(17):9561–9566CrossRefGoogle Scholar
  28. 28.
    Russo EB, Burnett A, Hall B, Parker KK (2005) Agonistic properties of cannabidiol at 5-HT1a receptors. Neurochem Res 30(8):1037–1043CrossRefGoogle Scholar
  29. 29.
    Hampson AJ, Grimaldi M, Axelrod J, Wink D (1998) Cannabidiol and (-)Delta9-tetrahydrocannabinol are neuroprotective antioxidants. Proc Natl Acad Sci U S A 95(14): 8268–8273CrossRefGoogle Scholar
  30. 30.
    Li K, Fichna J, Schicho R, Saur D, Bashashati M, Mackie K, Li Y, Zimmer A, Göke B, Sharkey KA, Storr M (2013) A role for O-1602 and G protein-coupled receptor GPR55 in the control of colonic motility in mice. Neuropharmacology 71:255–263CrossRefGoogle Scholar
  31. 31.
    Cunha JM, Carlini EA, Pereira AE, Ramos OL, Pimentel C, Gagliardi R, Sanvito WL, Lander N, Mechoulam R (1980) Chronic administration of cannabidiol to healthy volunteers and epileptic patients. Pharmacology 21(3):175–185CrossRefGoogle Scholar
  32. 32.
    Carlini EA, Cunha JM (1981) Hypnotic and antiepileptic effects of cannabidiol. J Clin Pharmacol 21(8–9 Suppl): 417S–427SGoogle Scholar
  33. 33.
    American Epilepsy Society (AES) 68th Annual Meeting. December 5–9, 2014, Seattle, Washington, USAGoogle Scholar
  34. 34.
    Zuardi AW, Cosme RA, Graeff FG, Guimarães FS (1993) Effects of ipsapirone and cannabidiol on human experimental anxiety. J Psychopharmacol 7(1 Suppl):82–88Google Scholar
  35. 35.
    Bergamaschi MM, Queiroz RH, Chagas MH, de Oliveira DC, De Martinis BS, Kapczinski F, Quevedo J, Roesler R, Schröder N, Nardi AE, Martín-Santos R, Hallak JE, Zuardi AW, Crippa JA (2011) Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naïve social phobia patients. Neuropsychopharmacology 36(6): 1219–1226CrossRefGoogle Scholar
  36. 36.
    Crippa JA, Derenusson GN, Ferrari TB, Wichert-Ana L, Duran FL, Martin-Santos R, Simões MV, Bhattacharyya S, Fusar-Poli P, Atakan Z, Santos Filho A, Freitas-Ferrari MC, McGuire PK, Zuardi AW, Busatto GF, Hallak JE (2011) Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: a preliminary report. J Psychopharmacol 25(1):121–130CrossRefGoogle Scholar
  37. 37.
    Zuardi AW, Crippa JA, Hallak JE, Pinto JP, Chagas MH, Rodrigues GG, Dursun SM, Tumas V (2009) Cannabidiol for the treatment of psychosis in Parkinson’s disease. J Psychopharmacol 23(8):979–983CrossRefGoogle Scholar
  38. 38.
    Leweke FM, Piomelli D, Pahlisch F, Muhl D, Gerth CW, Hoyer C, Klosterkötter J, Hellmich M, Koethe D (2012) Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. Transl Psychiatry 2:e94Google Scholar
  39. 39.
    Consroe P, Sandyk R, Snider SR (1986) Open label evaluation of cannabidiol in dystonic movement disorders. Int J Neurosci 30(4):277–282CrossRefGoogle Scholar
  40. 40.
    Crippa JA, Hallak JE, Machado-de-Sousa JP, Queiroz RH, Bergamaschi M, Chagas MH, Zuardi AW (2013) Cannabidiol for the treatment of cannabis withdrawal syndrome: a case report. J Clin Pharm Ther 38(2):162–164CrossRefGoogle Scholar
  41. 41.
    Chagas MH, Crippa JA, Zuardi AW, Hallak JE, Machado-de-Sousa JP, Hirotsu C, Maia L, Tufik S, Andersen ML (2013) Effects of acute systemic administration of cannabidiol on sleep-wake cycle in rats. J Psychopharmacol 27(3):312–316CrossRefGoogle Scholar
  42. 42.
    Chagas MH, Eckeli AL, Zuardi AW, Pena-Pereira MA, Sobreira-Neto MA, Sobreira ET, Camilo MR, Bergamaschi MM, Schenck CH, Hallak JE, Tumas V, Crippa JA (2014) Cannabidiol can improve complex sleep-related behaviours associated with rapid eye movement sleep behaviour disorder in Parkinson’s disease patients: a case series. J Clin Pharm Ther 39(5):564–566CrossRefGoogle Scholar
  43. 43.
    Nicholson AN, Turner C, Stone BM, Robson PJ (2004) Effect of Delta-9-tetrahydrocannabinol and cannabidiol on nocturnal sleep and early-morning behavior in young adults. J Clin Psychopharmacol 24(3):305–313CrossRefGoogle Scholar
  44. 44.
    Jiang R, Yamaori S, Okamoto Y, Yamamoto I, Watanabe K (2013) Cannabidiol is a potent inhibitor of the catalytic activity of cytochrome P450 2C19. Drug Metab Pharmacokinet 28(4):332–338CrossRefGoogle Scholar
  45. 45.
    Yamaori S, Koeda K, Kushihara M, Hada Y, Yamamoto I, Watanabe K (2012) Comparison in the in vitro inhibitory effects of major phytocannabinoids and polycyclic aromatic hydrocarbons contained in marijuana smoke on cytochrome P450 2C9 activity. Drug Metab Pharmacokinet 27(3):294–300CrossRefGoogle Scholar
  46. 46.
    Gallily R, Yekhtin Z, Hanuš LO (2015) Overcoming the bellshaped dose-response of cannabidiol by using cannabis extract enriched in cannabidiol. Pharmacol Pharm 6:75–85CrossRefGoogle Scholar
  47. 47.
    Borrelli F, Fasolino I, Romano B, Capasso R, Maiello F, Coppola D, Orlando P, Battista G, Pagano E, Di Marzo V, Izzo AA (2013) Beneficial effect of the non-psychotropic plant cannabinoid cannabigerol on experimental inflammatory bowel disease. Biochem Pharmacol 85(9):1306–1316CrossRefGoogle Scholar
  48. 48.
    Gertsch J, Leonti M, Raduner S, Racz I, Chen JZ, Xie XQ, Altmann KH, Karsak M, Zimmer A (2008) Beta-caryophyllene is a dietary cannabinoid. Proc Natl Acad Sci U S A 105(26):9099–9104CrossRefGoogle Scholar
  49. 49.
    Katsuyama S, Mizoguchi H, Kuwahata H, Komatsu T, Nagaoka K, Nakamura H, Bagetta G, Sakurada T, Sakurada S (2013) Involvement of peripheral cannabinoid and opioid receptors in β-caryophyllene-induced antinociception. Eur J Pain 17(5):664–675CrossRefGoogle Scholar

Copyright information

© CEC editore - Springer-Verlag Italia 2015

Authors and Affiliations

  • Francesco Di Pierro

There are no affiliations available

Personalised recommendations